Ascidian Therapeutics
Kirk Burkhart has extensive experience in the field of science. In 2020, they began working at Ascidian Therapeutics as a Principal Scientist, Senior Scientist, and Scientist II. From 2012 to 2020, they were a Postdoctoral Fellow at the Massachusetts Institute of Technology, where they discovered that the maternal inheritance of non-DNA based information can impact adult phenotypes. From 2006 to 2012, they were a Graduate Student at the University of Wisconsin-Madison, where they studied how RNA interference (RNAi) silences gene expression in the nucleus.
Kirk Burkhart received their Bachelor of Science (B.S.) in Microbiology, General from Michigan State University between 2001 and 2005. Kirk then went on to obtain their Doctor of Philosophy (PhD) in Genetics from the University of Wisconsin-Madison between 2006 and 2011.
This person is not in any teams
Ascidian Therapeutics
2 followers
Gene therapy is entering a new era as the field moves forward. But current technologies cannot overcome the challenges of many diseases. Ascidian’s unique approach aims to unlock these doors and enable treatment for millions of patients worldwide.